Shine Technologies, an advanced nuclear technology company and producer of lutetium-177, entered into a long-term supply agreement with Nucleus RadioPharma, a company involved in the development, manufacturing, and supply chain organization for radiopharmaceuticals.

Under the multi-year agreement, SHINE will provide lutetium-177 to Nucleus RadioPharma’s radioligand therapy (RLT) offerings for targeted radiopharmaceutical treatments for neuroendocrine tumors and prostate cancer.

The partnership ensures Nucleus will have an adequate supply of the radioisotope required for the use of their RLTs in clinical trials as they investigate the efficacy of targeted radiopharmaceuticals in additional cancer types.

Lutetium-177 is a key component for targeted radiopharmaceuticals, including those in development for the treatment of neuroendocrine tumors, prostate cancer, and other solid tumors. SHINE is at the forefront of creating non-carrier-added lutetium-177, using a breakthrough process that is more efficient, cost-effective, and environmentally friendly than existing production methods.

“Nucleus launched with the goal of addressing the scarcity of radionuclides and theranostics in production, which poses major challenges for patient care and clinical trials of new radiopharmaceuticals,” said Charles Conroy, CEO of Nucleus. “We are pleased to partner with SHINE, allowing us to utilize its dependable supply of lutetium-177 to develop highly effective treatments for cancer patients. We look forward to a long and productive partnership with SHINE to transform cancer care.”

“We are proud to partner with Nucleus RadioPharma to supply the high-purity lutetium-177 that powers their innovative radioligand therapy,” said Harrie Buurlage, chief commercial officer of Isotopes at SHINE Technologies. “This agreement demonstrates our ability to produce critical medical isotopes at commercial scale to enable new treatments that can improve patients’ lives.”

SHINE’s newly opened Wisconsin facility, Cassiopeia, is dedicated to producing non-carrier-added lutetium-177. According to the company, Cassiopeia is expected to produce up to 200,000 doses per year of critical medical isotopes that are often in short supply.